ArticleNature communications2022
Landscape of somatic alterations in large-scale solid tumors from an Asian population.
Abstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Locoregional gemcitabine plus surufatinib and camrelizumab in FGFR2-non-altered intrahepatic cholangiocarcinoma.Cell reports. Medicine · 2025Trial
- Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.International journal of cancer · 2026Article
- Age-stratified mutation patterns in early-onset colorectal cancer reveal distinct molecular features and therapeutic implications.ESMO gastrointestinal oncology · 2026Article
- Chromosomal Instability Drives Glioblastoma Heterogeneity and Therapeutic Opportunities.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Integrative proteomic characterization of human lung adenocarcinoma with KRAS G12 mutations reveals molecular pathogenesis.Journal of advanced research · 2026Article
- Sex-based molecular and prognostic disparities in pan-cancer: an analysis across the global cohorts.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- OncoRisk: a state-of-the-art web server for bridging the oncogenic databases and pan-cancer cohorts to the translational oncology.Communications biology · 2026Article
- Refining Tumor Mutational Burden as a Predictive Biomarker for Pembrolizumab: A Real-World Analysis in Japanese Patients.Cancer science · 2026Article
- The oncogenome of the domestic cat.Science (New York, N.Y.) · 2026Article
- Tumour mutation burden drives survival outcomes in pancreatic ductal adenocarcinoma and enables noninvasive prediction via dual-layer spectral CT.Insights into imaging · 2026Article
- HER2 and urothelial carcinoma: current understanding and future directions.Nature reviews. Urology · 2026Review
- Frequent EPHA2 receptor mutations in cholangiocarcinoma disrupt receptor forward signaling supporting a tumor suppressor role.Biochimica et biophysica acta. Molecular cell research · 2026Article
- Targeting notch signaling pathway in esophageal cancer: from molecular insights to therapies.Oncology reviews · 2026Review
- Somatic mutational profiling identifies aggressive and indolent disease phenotypes in well-differentiated pancreatic neuroendocrine tumors.Frontiers in oncology · 2026Article
- Tumors with mutations in chromatin regulators are associated with higher mutational burden and improved response to checkpoint immunotherapy.Clinical epigenetics · 2025Article
- Exploring KAT6 as a therapeutic target in breast cancer: epigenetic approaches for precision medicine.NPJ breast cancer · 2025Review
- Opportunities and challenges of immuno-oncology: A bibliometric analysis from 2014 to 2023.Human vaccines & immunotherapeutics · 2025Review
- The INSPECTOR study: enhanced feasibility for clinical translation of a multi-cancer early detection method based on enzyme-assisted high signal-to-noise ratio sequencing of methylated circulating tumor DNA.Cancer communications (London, England) · 2025Article
- Integrated circulating tumor DNA-based prognostic algorithm for limited stage small-cell lung cancer under definitive chemoradiotherapy and utility in consolidation immunotherapy benefit prediction.Cell communication and signaling : CCS · 2025Article
- Independent validation of lung adenocarcinoma prognostic risk scores incorporating cholesterol and estrogen metabolism related transcriptional biomarkers.Scientific reports · 2025Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
54 authors.
Liqun Wu *Department of Hepatobiliary Surgery, Affiliated Hospital of Qingdao University, Qingdao, China.
Herui Yao *Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Medical Oncology, Breast Tumor Center and Phase I Clinical Trial Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.ORCID 0000-0001-5520-6469
Hui Chen *Shanghai OrigiMed Co., Ltd, Shanghai, China.
Aodi WangShanghai OrigiMed Co., Ltd, Shanghai, China.
Kun GuoLiver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai, China.
Wenli GouDepartment of Obstetrics and Gynecology, First Affiliated Hospital of Xi'an Jiao Tong University, Xi'an, China.
Yanfei YuShanghai OrigiMed Co., Ltd, Shanghai, China.
Xiang LiShanghai OrigiMed Co., Ltd, Shanghai, China.
Ming YaoShanghai OrigiMed Co., Ltd, Shanghai, China.
Shaohua YuanShanghai OrigiMed Co., Ltd, Shanghai, China.
Fei PangShanghai OrigiMed Co., Ltd, Shanghai, China.
Jinwei HuShanghai OrigiMed Co., Ltd, Shanghai, China.
Lijuan ChenShanghai OrigiMed Co., Ltd, Shanghai, China.
Wenjin LiuShanghai OrigiMed Co., Ltd, Shanghai, China.
Jicheng YaoShanghai OrigiMed Co., Ltd, Shanghai, China.
Shuirong ZhangShanghai OrigiMed Co., Ltd, Shanghai, China.
Xiaowei DongShanghai OrigiMed Co., Ltd, Shanghai, China.
Weifeng WangShanghai OrigiMed Co., Ltd, Shanghai, China.
Jing HuDepartment of Medical Oncology, The First People's Hospital of Yunnan Province, Kunming, China.
Qi LingDepartment of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.ORCID 0000-0002-7377-2381
Songming DingDepartment of Hepatobiliary and Pancreatic Surgery, Shu Lan (Hangzhou) Hospital, Hangzhou, China.
Yan WeiDepartment of Oncology, Guigang City People's Hospital, The Eighth Affiliated Hospital of Guangxi Medical University, Guigang, China.
Qiang LiDepartment of Hepatobiliary Surgery, Affiliated Hospital of North Sichuan Medical University, Nanchong, China.
Weichun CaoDepartment of Gynecologic Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
Shuang WangDepartment of Pathology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.
Yang DiDepartment of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China.
Feiling FengDepartment of Biliary Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, Shanghai, China.
Gang ZhaoDepartment of Pathology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Jian ZhangDepartment of General Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Ling HuangDepartment of Gastrointestinal Oncology, Huifuxi Branch of Guangdong Provincial People's Hospital, Guangzhou, China.
Jia XuDepartment of Emergency, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Wangjun YanDepartment of Musculoskeletal Surgery, Shanghai Cancer Center, Fudan University, Shanghai, China.
Zhongsheng TongDepartment of Breast Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Da JiangDepartment of Oncology, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Tao JiMusculoskeletal Tumor Center, Beijing Key Laboratory for Musculoskeletal Tumors, People's Hospital, Peking University, Beijing, China.ORCID 0000-0001-6876-7361
Qiao LiNational Cancer Center/ Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Ling XuBreast Disease Center, Peking University First Hospital, Beijing, China.
Huiying HeDepartment of Pathology, School of Basic Medical Sciences, Third Hospital, Peking University, Beijing, China.ORCID 0000-0001-6237-2190
Liang ShangDepartment of Gastrointestinal Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Jin LiuDepartment of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Kefeng WangDepartment of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Duoguang WuDepartment of Thoracic Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
Jingnan ShenDepartment of Musculoskeletal Oncology, First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.ORCID 0000-0001-7471-2746
Ye LiuDepartment of Pathology, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, China.
Ting ZhangDepartment of Bone Marrow, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
Chaojie LiangDepartment of General Surgery, The First Hospital of Shanxi Medical University, Taiyuan, China.
Yusheng WangDepartment of Digestive, Shanxi Provincial Cancer Hospital, Taiyuan, China.
Yanhong ShangDepartment of Medical Oncology, The Affiliated Hospital, Hebei University, Baoding, China.
Jianji GuoDepartment of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Guanbiao LiangDepartment of Thoracic Surgery, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Shifeng XuDepartment of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China.
Junfeng LiuDepartment of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, China.
Kai WangShanghai OrigiMed Co., Ltd, Shanghai, China. wangk@origimed.com.ORCID 0000-0002-8272-2888
Minghui WangGuangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Department of Thoracic Surgery, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, 510120, Guangzhou, China. wmingh@mail.sysu.edu.cn.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extending the benefits of tumor molecular profiling for all cancer patients requires a comprehensive analysis of tumor genomes across distinct patient populations worldwide. In this study, we perform deep next-generation DNA sequencing (NGS) from tumor tissues and matched blood specimens from over 10,000 patients in China by using a 450-gene comprehensive assay, developed and implemented under international clinical regulations. We perform a comprehensive comparison of somatically altered genes, the distribution of tumor mutational burden (TMB), gene fusion patterns, and the spectrum of various somatic alterations between Chinese and American patient populations. Here, we show 64% of cancers from Chinese patients in this study have clinically actionable genomic alterations, which may affect clinical decisions related to targeted therapy or immunotherapy. These findings describe the similarities and differences between tumors from Chinese and American patients, providing valuable information for personalized medicine.
Indexed as
NeoplasmsAsian PeopleBiomarkers, TumorHigh-Throughput Nucleotide SequencingHumansMutationPrecision MedicineBiomarkers, Tumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.